Company intelligence / Profile preview
ENB Therapeutics
New York City, New York, United Statesenbpharma.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
ENB’s lead candidate (ENB‑003), a selective small molecule ETBR inhibitor, has received IND approval from the FDA and entered clinical trials in combination with pembrolizumab for patients with drug-resistant melanoma and ovarian or pancreatic cancers. Preclinical data show efficacy in multiple solid tumors by converting “cold” tumors to “hot” and promoting TLO formation. Clinical results are not yet published but early-stage trials are ongoing.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on ENB Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENB Therapeutics.